Intellia Therapeutics, Inc. (NTLA) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 82.2% | -923.1% | -896.8% |
| 2023 | 75.3% | -1420.5% | -1326.5% |
| 2022 | 85.5% | -879.0% | -909.8% |
| 2021 | 79.2% | -810.4% | -810.5% |
Download Data
Export NTLA earnings history in CSV or JSON format
Free sign-in required to download data
Intellia Therapeutics, Inc. (NTLA) Earnings Overview
As of March 1, 2026, Intellia Therapeutics, Inc. (NTLA) reported trailing twelve-month net income of -$413M, reflecting +0.3% year-over-year growth. The company earned $-3.81 per diluted share over the past four quarters.
Looking at the long-term picture, NTLA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2015.
Intellia Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), NTLA has comparable earnings metrics. Compare NTLA vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$413M | +20.5% | $0 | $-3.81 | - | - |
| 2024 | -$519M | -7.9% | -$534M | $-5.25 | -896.8% | -923.1% |
| 2023 | -$481M | -1.5% | -$515M | $-5.42 | -1326.5% | -1420.5% |
| 2022 | -$474M | -77.0% | -$458M | $-6.16 | -909.8% | -879.0% |
| 2021 | -$268M | -99.6% | -$268M | $-3.78 | -810.5% | -810.4% |
| 2020 | -$134M | -34.9% | -$137M | $-2.40 | -231.5% | -235.5% |
| 2019 | -$100M | -16.6% | -$106M | $-1.96 | -230.9% | -246.8% |
| 2018 | -$85M | -26.4% | -$91M | $-1.98 | -280.4% | -298.6% |
| 2017 | -$68M | -113.5% | -$70M | $-1.88 | -258.6% | -266.3% |
| 2016 | -$32M | -155.2% | -$32M | $-0.91 | -192.0% | -195.2% |
See NTLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NTLA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NTLA vs AGIO
See how NTLA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NTLA growing earnings?
NTLA EPS of $-3.81 reflects slowing growth at +0.3%, below the 5-year CAGR of N/A. TTM net income is $-413M. Expansion rate has moderated.
What are NTLA's profit margins?
Intellia Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NTLA's earnings?
NTLA earnings data spans 2014-2025. The current earnings trend is +0.3% YoY. Historical data enables comparison across business cycles.